Does Bacteriotherapy Improve Tonsillar and Nasal Microbiota in Young Patients with Influenza A/H3N2, A/H2N2 & Type B?

This study investigates the species composition and population levels of nasal and tonsillar microbiota in young patients with Influenza A/H3N2, A/H2N2, and Type B. The contamination of mucous membranes with bacterial strains such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Streptococcus pneumoniae, and fungi of the Candida genus was determined. In vitro studies revealed that Bacillus subtilis and Bacillus licheniformis strains exhibit significant antagonistic activity, inhibiting bacterial growth by 24.15% after 24 hours, 44.65% after 48 hours, and 58.94% after 72 hours. Streptococcus pyogenes showed a consistent reduction in population, reaching up to 73.33% inhibition at 72 hours. A notable decrease in pathogenic and opportunistic organisms was observed, with complete elimination of several species, including S. aureus and K. pneumoniae, on the tonsillar and nasal mucosae (p<0.05). These findings suggest that bacteriotherapy may effectively manage and reduce pathogenic bacterial populations in influenza-infected patients.